{"id":65722,"date":"2026-05-19T23:47:50","date_gmt":"2026-05-19T15:47:50","guid":{"rendered":"https:\/\/flcube.com\/?p=65722"},"modified":"2026-05-19T23:47:51","modified_gmt":"2026-05-19T15:47:51","slug":"boston-scientific-invests-1-5b-for-34-stake-in-mirus-secures-option-to-acquire-siegel-tavr-business-for-additional-3b","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65722","title":{"rendered":"Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B"},"content":{"rendered":"\n<p><strong>Boston Scientific Corporation<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BSX:NYSE\">NYSE: BSX<\/a>) announced a <strong>strategic $1.5 billion investment<\/strong> for an <strong>approximately 34% equity stake<\/strong> in <strong>MiRus LLC<\/strong>, a privately-held developer of <strong>proprietary biomaterials and cardiovascular implants<\/strong>. The transaction includes an <strong>option for Boston Scientific to acquire MiRus&#8217; transcatheter aortic valve replacement (TAVR) business<\/strong> for an additional <strong>$3 billion<\/strong> upon achievement of clinical and regulatory milestones, potentially gaining <strong>100% ownership<\/strong> of the <strong>SIEGEL Balloon Expandable TAVR system<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investment-structure-amp-option-framework\">Investment Structure &amp; Option Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Value<\/th><th>Terms<\/th><\/tr><\/thead><tbody><tr><td><strong>Initial Equity Investment<\/strong><\/td><td>$1.5 billion<\/td><td>34% ownership stake in MiRus LLC<\/td><\/tr><tr><td><strong>TAVR Business Acquisition Option<\/strong><\/td><td>$3 billion<\/td><td>Contingent on clinical\/regulatory milestones<\/td><\/tr><tr><td><strong>Total Potential Investment<\/strong><\/td><td>$4.5 billion<\/td><td>Full TAVR business ownership<\/td><\/tr><tr><td><strong>Additional Consideration<\/strong><\/td><td>Sales-based payments<\/td><td>Net sales royalties on SIEGEL TAVR over specified period<\/td><\/tr><tr><td><strong>Future Asset Options<\/strong><\/td><td>Undisclosed<\/td><td>Exclusive option to acquire mitral\/tricuspid valve assets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mirus-portfolio-amp-technology-platform\">MiRus Portfolio &amp; Technology Platform<\/h2>\n\n\n\n<p><strong>MiRus LLC<\/strong> has developed a <strong>comprehensive biomaterials and implant platform<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Core Technology<\/strong>: Proprietary biomaterials enabling advanced cardiovascular and orthopedic solutions<\/li>\n\n\n\n<li><strong>Lead Product<\/strong>: <strong>SIEGEL Balloon Expandable TAVR system<\/strong> for transcatheter aortic valve replacement<\/li>\n\n\n\n<li><strong>Pipeline Expansion<\/strong>: <strong>Mitral and tricuspid replacement valve assets<\/strong> under development<\/li>\n\n\n\n<li><strong>Therapeutic Focus<\/strong>: Integrated solutions for <strong>cardiovascular and orthopedic diseases<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-for-boston-scientific\">Strategic Rationale for Boston Scientific<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TAVR Market Leadership<\/strong>: Strengthens position in <strong>$8+ billion global TAVR market<\/strong> growing at 12% CAGR<\/li>\n\n\n\n<li><strong>Technology Diversification<\/strong>: Adds <strong>balloon-expandable TAVR<\/strong> to complement existing portfolio approaches<\/li>\n\n\n\n<li><strong>Innovation Pipeline<\/strong>: Gains access to <strong>next-generation structural heart technologies<\/strong> beyond aortic valve<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: Counters Medtronic, Edwards Lifesciences, and Abbott in premium TAVR segment<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-milestone-driven-acquisition-strategy\">Milestone-Driven Acquisition Strategy<\/h2>\n\n\n\n<p>The <strong>contingent acquisition structure<\/strong> provides Boston Scientific with strategic flexibility:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>De-risked Investment<\/strong>: Initial $1.5B stake provides portfolio diversification while validating technology<\/li>\n\n\n\n<li><strong>Performance-Based Option<\/strong>: $3B TAVR acquisition contingent on <strong>clinical trial success<\/strong> and <strong>regulatory approvals<\/strong><\/li>\n\n\n\n<li><strong>Commercial Validation<\/strong>: Milestones likely tied to <strong>pivotal trial results<\/strong> and <strong>FDA\/CE Mark approval<\/strong><\/li>\n\n\n\n<li><strong>Expansion Rights<\/strong>: Success triggers additional options for <strong>mitral and tricuspid valve programs<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TAVR Market Dynamics<\/strong>: Highly competitive space dominated by <strong>Edwards Lifesciences (SAPIEN)<\/strong>, <strong>Medtronic (Evolut)<\/strong>, and <strong>Abbott (Navitor)<\/strong><\/li>\n\n\n\n<li><strong>Balloon-Expandable Segment<\/strong>: Edwards currently leads this technical approach, creating opportunity for differentiated entrant<\/li>\n\n\n\n<li><strong>Structural Heart Growth<\/strong>: Transcatheter valve market projected to reach <strong>$15 billion by 2030<\/strong> across all valve positions<\/li>\n\n\n\n<li><strong>Chinese Market Access<\/strong>: MiRus&#8217; biomaterials expertise may provide advantages in <strong>emerging market regulatory pathways<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications-amp-valuation\">Financial Implications &amp; Valuation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Enterprise Valuation<\/strong>: $1.5B for 34% implies <strong>~$4.4B pre-money valuation<\/strong> for MiRus<\/li>\n\n\n\n<li><strong>TAVR Business Value<\/strong>: Additional $3B suggests TAVR segment valued at <strong>~$68% of total enterprise value<\/strong><\/li>\n\n\n\n<li><strong>Capital Allocation<\/strong>: Represents significant but strategic use of Boston Scientific&#8217;s <strong>strong balance sheet<\/strong><\/li>\n\n\n\n<li><strong>Return Potential<\/strong>: Successful TAVR commercialization could generate <strong>$1B+ annual revenue<\/strong> at peak penetration<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-clinical-pathway\">Regulatory &amp; Clinical Pathway<\/h2>\n\n\n\n<p>While specific milestones weren&#8217;t disclosed, typical TAVR development requirements include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pivotal Trial Completion<\/strong>: Likely ongoing or planned <strong>U.S. IDE study<\/strong> demonstrating safety and efficacy<\/li>\n\n\n\n<li><strong>FDA Approval<\/strong>: PMA submission and approval for <strong>high-risk and intermediate-risk patient populations<\/strong><\/li>\n\n\n\n<li><strong>CE Mark<\/strong>: European regulatory clearance enabling commercial launch in key international markets<\/li>\n\n\n\n<li><strong>Reimbursement<\/strong>: CMS and private payer coverage decisions supporting commercial adoption<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-integration-considerations\">Strategic Integration Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing Synergies<\/strong>: Boston Scientific&#8217;s <strong>global manufacturing infrastructure<\/strong> could accelerate scale-up<\/li>\n\n\n\n<li><strong>Commercial Leverage<\/strong>: Existing <strong>structural heart sales force<\/strong> provides immediate market access<\/li>\n\n\n\n<li><strong>R&amp;D Enhancement<\/strong>: MiRus&#8217; biomaterials expertise strengthens Boston Scientific&#8217;s <strong>innovation capabilities<\/strong><\/li>\n\n\n\n<li><strong>Geographic Expansion<\/strong>: Combined resources enable faster <strong>global market penetration<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-risk-mitigation-amp-optionality\">Risk Mitigation &amp; Optionality<\/h2>\n\n\n\n<p>The structured deal provides multiple layers of risk management:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Diversification<\/strong>: Initial investment provides exposure to <strong>multiple MiRus programs<\/strong> beyond TAVR<\/li>\n\n\n\n<li><strong>Milestone Gatekeeping<\/strong>: Performance requirements ensure <strong>technology validation<\/strong> before major commitment<\/li>\n\n\n\n<li><strong>Asset Flexibility<\/strong>: Option structure allows Boston Scientific to <strong>adapt strategy<\/strong> based on market evolution<\/li>\n\n\n\n<li><strong>Competitive Response<\/strong>: Positions Boston Scientific to <strong>counter competitor innovations<\/strong> in structural heart space<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding strategic investments, regulatory approvals, and commercial expectations. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption patterns.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston Scientific Corporation (NYSE: BSX) announced a strategic $1.5 billion investment for an approximately 34%&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[315,4746,1160],"class_list":["post-65722","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-boston-scientific","tag-mirus","tag-nyse-bsx"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Boston Scientific Corporation (NYSE: BSX) announced a strategic $1.5 billion investment for an approximately 34% equity stake in MiRus LLC, a privately-held developer of proprietary biomaterials and cardiovascular implants. The transaction includes an option for Boston Scientific to acquire MiRus&#039; transcatheter aortic valve replacement (TAVR) business for an additional $3 billion upon achievement of clinical and regulatory milestones, potentially gaining 100% ownership of the SIEGEL Balloon Expandable TAVR system.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65722\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B\" \/>\n<meta property=\"og:description\" content=\"Boston Scientific Corporation (NYSE: BSX) announced a strategic $1.5 billion investment for an approximately 34% equity stake in MiRus LLC, a privately-held developer of proprietary biomaterials and cardiovascular implants. The transaction includes an option for Boston Scientific to acquire MiRus&#039; transcatheter aortic valve replacement (TAVR) business for an additional $3 billion upon achievement of clinical and regulatory milestones, potentially gaining 100% ownership of the SIEGEL Balloon Expandable TAVR system.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65722\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-19T15:47:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-19T15:47:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65722#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65722\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B\",\"datePublished\":\"2026-05-19T15:47:50+00:00\",\"dateModified\":\"2026-05-19T15:47:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65722\"},\"wordCount\":643,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Boston Scientific\",\"MiRus\",\"NYSE: BSX\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65722#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65722\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65722\",\"name\":\"Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-19T15:47:50+00:00\",\"dateModified\":\"2026-05-19T15:47:51+00:00\",\"description\":\"Boston Scientific Corporation (NYSE: BSX) announced a strategic $1.5 billion investment for an approximately 34% equity stake in MiRus LLC, a privately-held developer of proprietary biomaterials and cardiovascular implants. The transaction includes an option for Boston Scientific to acquire MiRus' transcatheter aortic valve replacement (TAVR) business for an additional $3 billion upon achievement of clinical and regulatory milestones, potentially gaining 100% ownership of the SIEGEL Balloon Expandable TAVR system.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65722#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65722\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65722#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B - Insight, China&#039;s Pharmaceutical Industry","description":"Boston Scientific Corporation (NYSE: BSX) announced a strategic $1.5 billion investment for an approximately 34% equity stake in MiRus LLC, a privately-held developer of proprietary biomaterials and cardiovascular implants. The transaction includes an option for Boston Scientific to acquire MiRus' transcatheter aortic valve replacement (TAVR) business for an additional $3 billion upon achievement of clinical and regulatory milestones, potentially gaining 100% ownership of the SIEGEL Balloon Expandable TAVR system.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65722","og_locale":"en_US","og_type":"article","og_title":"Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B","og_description":"Boston Scientific Corporation (NYSE: BSX) announced a strategic $1.5 billion investment for an approximately 34% equity stake in MiRus LLC, a privately-held developer of proprietary biomaterials and cardiovascular implants. The transaction includes an option for Boston Scientific to acquire MiRus' transcatheter aortic valve replacement (TAVR) business for an additional $3 billion upon achievement of clinical and regulatory milestones, potentially gaining 100% ownership of the SIEGEL Balloon Expandable TAVR system.","og_url":"https:\/\/flcube.com\/?p=65722","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-19T15:47:50+00:00","article_modified_time":"2026-05-19T15:47:51+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65722#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65722"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B","datePublished":"2026-05-19T15:47:50+00:00","dateModified":"2026-05-19T15:47:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65722"},"wordCount":643,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Boston Scientific","MiRus","NYSE: BSX"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65722#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65722","url":"https:\/\/flcube.com\/?p=65722","name":"Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-19T15:47:50+00:00","dateModified":"2026-05-19T15:47:51+00:00","description":"Boston Scientific Corporation (NYSE: BSX) announced a strategic $1.5 billion investment for an approximately 34% equity stake in MiRus LLC, a privately-held developer of proprietary biomaterials and cardiovascular implants. The transaction includes an option for Boston Scientific to acquire MiRus' transcatheter aortic valve replacement (TAVR) business for an additional $3 billion upon achievement of clinical and regulatory milestones, potentially gaining 100% ownership of the SIEGEL Balloon Expandable TAVR system.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65722#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65722"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65722#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65722","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65722"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65722\/revisions"}],"predecessor-version":[{"id":65723,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65722\/revisions\/65723"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65722"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65722"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65722"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}